HBM gets health boost from drug licensing deals
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer Key Takeaways: Nona Biosciences, a subsidiary of…
2142.HK
Recent Articles
RELATED ARTICLES
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
Everest reaches new heights on growing drug sales
1952.HK
Discover hidden China stock gems in our weekly newsletter